In plain words
In five placebo-controlled trials, people who took NMN by mouth for two weeks to three months had more NAD or its breakdown products in their blood than people on placebo. In the hours after a single dose, two studies saw no rise in NMN itself in the blood.
The short answer
All five randomized trials found higher blood NAD or NAD breakdown products with NMN than with placebo: 15 people on 1 g a day for 14 days, 32 on 1,000 mg once or twice daily for 14 days, 34 and 60 on 250 mg a day for 12 weeks, and 80 on 300 to 900 mg a day for 60 days. In the hours after one dose, blood NMN itself did not change in the 14-day trial of 15 people or in a before-after study of 13 people. Certainty is moderate: the trials agree, but they are small and none ran past 12 weeks.
Where the evidence sits
Higher NAD or breakdown products
■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data
Who says what
| Source | Finding | Design | People | Dose and length | Funding and independence |
|---|---|---|---|---|---|
| Christen, 2026 | NAD+ higher | Randomized trial | 15 | 1 g, 14 days | Not in ledger |
| Pencina, 2023 | NMN higher | Randomized trial | 32 | 1,000 mg, 14 days | Not in ledger |
| Katayoshi, 2023 | Nicotinamide higher | Randomized trial | 34 | 250 mg, 12 weeks | Not in ledger |
| Morifuji, 2024 | NAD+ higher | Randomized trial | 60 | 250 mg, 12 weeks | Not in ledger |
| Yi, 2022 | NAD higher | Randomized trial | 80 | 300 to 900 mg, 60 days | Not in ledger |
| Wakabayashi, 2026 | NMN unchanged | Before-after study | 13 | 250 mg once | Not in ledger |
| Irie, 2019 | Breakdown products rose | Before-after study | 10 | Up to 500 mg once | Not in ledger |
| Zhang, 2024 | NAD higher | Meta-analysis; may include the trials above | 513 | Not in ledger | Not in ledger |
NAD+ higher
NMN higher
Nicotinamide higher
NAD+ higher
NAD higher
NMN unchanged
Breakdown products rose
NAD higher
Did blood NAD rise over weeks of use?
Yi and colleagues (2022) gave 80 healthy middle-aged adults 300, 600 or 900 mg a day, or placebo, for 60 days:
Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to both placebo and baseline (all p ≤ 0.001).
Morifuji and colleagues (2024) found higher blood NAD+ and metabolites than placebo in 60 adults on 250 mg a day for 12 weeks.
Does NMN itself reach the blood?
Christen and colleagues (2026) sampled blood for 4 hours after a 1 g dose in 15 people:
the low NR and NMN concentrations in whole blood ( < 2 µM) were not affected
After 14 days at 1 g a day, whole-blood NAD+ in those 15 people was 43.1 µM above placebo. Wakabayashi and colleagues (2026), in a before-after study of 13 people given 250 mg once, saw no change in blood NMN over 60 minutes; NAD+ was higher at 30 minutes when NMN was taken under the tongue.
Were the trials measuring the same molecule?
Katayoshi and colleagues (2023) gave 34 adults 250 mg a day or placebo for 12 weeks:
NAD+ and NMN in the serum were detectable in both groups, but the values were below the lower limit of quantification.
Serum nicotinamide, an NAD+ metabolite, was higher with NMN in that trial. Yi measured serum NAD+ plus NADH, and Christen measured whole blood. Irie and colleagues (2019) measured two breakdown products, which rose with dose in a before-after study of 10 people given 100, 250 or 500 mg once and followed for 5 hours.
Why the sources disagree
No independent measurements contradict each other; the studies differ in timing and measure. The two single-dose studies followed people for 1 to 4 hours and saw no rise in blood NMN itself, while Pencina found blood NMN higher in 32 adults after 14 days of 1,000 mg once or twice daily. The trials measured whole blood, serum or breakdown products. The ledger has no funding details for any source.
What would settle it
An independent, placebo-controlled trial of oral NMN at 250 and 1,000 mg a day for at least six months, measuring whole-blood NMN, NAD+ and breakdown products with one assay at baseline, 2, 6 and 24 hours after the first dose, then monthly, with a pre-registered analysis and disclosed funding.
How this page was made
The 8 sources are 7 human studies and one meta-analysis, a pooled estimate that may include the trials above, found through a PubMed search for human NMN studies; studies of other precursors, disease groups, animals and unpublished protocols were left out. Every claim was copied word for word from its source into the Longevity Circle ledger and checked against the original text, and a person approved each one. "Leaning" means the independent studies point mostly one way; certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.
Changelog: 28 Sep 2026, first version, 8 sources.
